WALTHAM,
Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
clinical-stage biotechnology company utilizing best-in-class
antibody engineering, rational therapeutic combinations, and
precision medicine approaches to target improved efficacy and
convenience in the treatment of inflammatory bowel disease ("IBD"),
today announced the appointment of Sheldon
Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr.
Sloan brings more than 25 years of experience in both large
pharmaceutical and small biotech companies with an extensive track
record of program leadership in the field of Inflammation and
Immunology. This includes more than 15 years in various leadership
roles at J&J, followed by Vice President and program lead for
estrasimod in ulcerative colitis at Arena Pharmaceuticals ("Arena")
and Pfizer, and most recently CMO and program lead for obefazimod
in ulcerative colitis at Abivax S.A. ("Abivax").
"Sheldon's distinguished career provides numerous examples of
the talent, leadership, and determination required to create and
deliver innovative new therapies to patients in need," said
Cameron Turtle, DPhil, chief
executive officer of Spyre. "We have an ambitious roadmap ahead of
us as we continue our effort to advance each of our programs into
the clinic over the next several months and initiate Phase 2
studies in 2025. We are grateful to have Sheldon on board to scale
and lead our medical organization to deliver on these goals."
Dr. Sloan is the former Chief Medical Officer at Abivax where he
led the Phase 3 development of obefazimod, responsible for medical
strategy, lifecycle strategy, and building medical infrastructure
including Clinical Development, Pharmacovigilance, Bioinformatics,
Medical Affairs, and Clinical Pharmacology. Prior to Abivax, Dr.
Sloan led the development of etrasimod at Arena, and Pfizer, after
Arena's acquisition, where he was responsible for planning,
execution, and global submission of the ulcerative colitis program.
Prior to joining Arena, Dr. Sloan held leadership positions at
J&J in Medical Affairs, R&D, and Science Policy. In his
last position at J&J, he was Global Medical Affairs Lead for
IBD, responsible for the global launch in Crohn's disease and
ulcerative colitis for Stelara. Dr. Sloan holds an M.D. from Rush
Medical College, and a Master of Bioethics from the University of Pennsylvania. Dr. Sloan currently
serves on the Columbia University
Masters of Bioethics Advisory Board, the Drexel University Dornsife School of Public Health
Dean's Impact, Advancement and Learning Council, and the American
Gastroenterological Association Ethics Committee.
"Spyre is pursuing what I believe to be an unrivaled strategy in
the field by engineering potentially best-in-class antibodies
against the top targets within IBD and advancing them as
combination product candidates with the potential to be delivered
on an infrequent basis," said Dr. Sloan. "I'm excited to join the
team and continue to build its medical organization to advance
Spyre's programs into Phase 2 studies in 2025."
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation of inflammatory bowel disease
(IBD) products by combining best-in-class antibody engineering,
rational therapeutic combinations, and precision medicine
approaches. Spyre's pipeline includes investigational extended
half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please
visit http://spyre.com.
Forward-Looking Statements
This press release
contains "forward-looking" statements within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. All statements contained in this press release,
other than statements of historical fact are forward-looking
statements. These forward-looking statements include statements
regarding the Company's business strategy, including the Company's
potential success of developing therapeutics for IBD, the potential
contributions of Dr. Sloan, including the development of the
Company's medical organization to advance its programs into Phase 2
studies in 2025, the potential efficacy and safety profile of its
product candidates, the potential therapeutic benefits of its
product candidates and the timing of clinical trials, including the
commencement of Phase 2 studies. The words "believe," "may,"
"will," "potentially," "estimate," "continue," "anticipate,"
"predict," "target," "intend," "could," "would," "should,"
"project," "plan," "expect," the negatives of these terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements involve a
number of risks, uncertainties (some of which are beyond Spyre's
control) or other assumptions that may cause actual results or
performance to be materially different from those expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited those uncertainties and
factors described under the heading "Risk Factors" and "Note about
Forward-Looking Statements" in Spyre's most recent Quarterly Report
on Form 10-Q filed with the SEC, as well as discussions of
potential risks, uncertainties, and other important factors
included in other filings by Spyre from time to time. Should one or
more of these risks or uncertainties materialize, or should any of
Spyre's assumptions prove incorrect, actual results may vary in
material respects from those projected in these forward-looking
statements. Nothing in this press release should be regarded as a
representation by any person that the forward-looking statements
set forth therein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements in
this press release, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary
statements herein. Spyre does not undertake or accept any duty to
make any updates or revisions to any forward-looking statements.
This press release does not purport to summarize all of the
conditions, risks and other attributes of an investment in
Spyre.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-appoints-dr-sheldon-sloan-as-chief-medical-officer-302261547.html
SOURCE Spyre Therapeutics, Inc.